Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity-A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

被引：1
|
作者：
Aronne, Louis
Harris, M. Scott
Roberts, M. S.
Suschak, John J.
Tomah, Shaheen
Kasper, Jonathan
He, Liang
Yang, Jay
Frias, Juan P.
Browne, Sarah K.
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-262-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
262-OR
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 2, randomised, placebo-controlled trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis
    Aronne, L.
    Harris, M. S.
    Roberts, M. S.
    Suschak, J.
    Tomah, S.
    He, L.
    Yang, J.
    Frias, J. P.
    Browne, S. K.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S33 - S34
  • [2] Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids
    Suschak, John J.
    Georges, Bertrand
    Roberts, M. S.
    Harris, M. Scott
    Browne, Sarah K.
    DIABETES, 2024, 73
  • [3] Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
    Roux, Carel W. le
    Steen, Oren
    Lucas, Kathryn J.
    Startseva, Elena
    Unseld, Anna
    Hennige, Anita M.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (03): : 162 - 173
  • [4] Survodutide, a glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity: analysis of a placebo-controlled, randomised phase 2 trial
    Le Roux, C.
    Steen, O.
    Lucas, K. J.
    Ekinci, E., I
    Startseva, E.
    Unseld, A.
    Hennige, A. M.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [5] Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo- controlled study
    Harrison, Stephen A.
    Browne, Sarah K.
    Suschak, John J.
    Tomah, Shaheen
    Gutierrez, Julio A.
    Yang, Jay
    Roberts, M. Scot
    Harris, M. Scott
    JOURNAL OF HEPATOLOGY, 2025, 82 (01)
  • [6] Once-weekly triple receptor (GIP/GLP-1/glucagon) agonist retatrutide (LY3437943): efficacy and safety in a 48-week obesity phase 2 trial
    Jastreboff, A. M.
    Kaplan, L. M.
    Frias, J. P.
    Wu, Q.
    Du, Y.
    Gurbuz, S.
    Coskun, T.
    Haupt, A.
    Milicevic, Z.
    Hartman, M. L.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S32 - S32
  • [7] Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators
    Plutzky, Jorge
    Harris, M. Scott S.
    Alonso, Cristina
    Suschak, John
    Noor, Mustafa
    Ortiz, Pablo
    Georges, Bertrand
    Rader, Daniel J.
    Roberts, Scot S.
    Browne, Sarah K.
    CIRCULATION, 2022, 146
  • [8] Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial
    Sanyal, Arun J.
    Bedossa, Pierre
    Fraessdorf, Mandy
    Neff, Guy
    Lawitz, Eric
    Bugianesi, Elisabetta
    Anstee, Quentin M.
    Hussain, Samina Ajaz
    Newsome, Philip N.
    Ratziu, Vlad
    Hosseini-Tabatabaei, Azadeh
    Schattenberg, Joern M.
    Noureddin, Mazen
    Alkhouri, Naim
    Younes, Ramy
    JOURNAL OF HEPATOLOGY, 2024, 80 : S4 - S5
  • [9] Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
    Ji, Linong
    Gao, Leili
    Jiang, Hongwei
    Yang, Jing
    Yu, Lei
    Wen, Jie
    Cai, Chenghang
    Deng, Huan
    Feng, Liqi
    Song, Baili
    Ma, Qingyang
    Qian, Lei
    ECLINICALMEDICINE, 2022, 54
  • [10] Pemvidutide (ALT-801), a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity
    Klein, Samuel
    Nestor, John J.
    Harris, M. Scott
    Suyundikov, Anvar
    Casper, Rob
    Steele, Staci M.
    Payne, Jacques D.
    Krishnan, Vyjayanthi
    Roberts, M. Scot
    Browne, Sarah K.
    DIABETES, 2022, 71
12345